The flotation of US-based liver drugs maker Intercept Pharmaceuticals, majority owned by Genextra, came in October.

Double chin removing healthcare company Kythera Biopharmaceuticals backed by Foley Ventures, the corporate venturing unit of law firm Foley & Lardner, floats on October 10.

Roche Venture Fund and MedImmune Ventures are in the E round.

Shionogi owns 12.5% of Enanta before its initial public offering, while Abbott Labs has 8.38%.

Elghandour had been a principal at Johnson & Johnson Development Corporation (JJDC) for four years and would join Nevro, according to news provider Fortune.

Biotechnology company Ziarco has closed the first round of its series A round with $6m.

Regulus Therapeutics has raised $80.9m in total proceeds from its initial public offering, a private placement, and convertible note.

Germany-based pharmaceutical company Merck has spun off Asceneuron and invested $6.5m of seed funding for the development of its Alzheimer therapies.